Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of subcutaneous GLP-1 receptor agonists versus SGLT2 inhibitors on metabolic and hepatic outcomes in T2DM with MASLD: a propensity score-matched study.

Journal of endocrinological investigation·2026
Same author

Predicted risk of death and frequency of outpatient follow-up visits in diabetes clinics. Insight from the large, real-life Italian AMD-Annals database.

Diabetes research and clinical practice·2026
Same author

Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative.

Acta diabetologica·2026
Same author

Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.

International journal of molecular sciences·2026
Same author

A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.

Journal of clinical medicine·2026
Same author

Skin Application of Inflammasome Inhibitor MCC950 Prevents Psoriasis-like Cutaneous Manifestations and Associated Systemic Inflammation.

Inflammation·2026

Related Experiment Video

Updated: Jun 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

TRAIL shows potential cardioprotective activity.

Barbara Toffoli1, Stella Bernardi, Riccardo Candido

  • 1Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.

Investigational New Drugs
|January 4, 2011
PubMed
Summary

Recombinant TRAIL (TNF-related apoptosis-inducing ligand) shows promise in protecting against chemotherapy-induced cardiomyopathy. This study found TRAIL reduced heart damage in a diabetic mouse model, suggesting a potential cardioprotective therapy.

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Related Experiment Videos

Last Updated: Jun 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Area of Science:

  • Cardiovascular Research
  • Oncology
  • Molecular Biology

Background:

  • Recombinant TRAIL (TNF-related apoptosis-inducing ligand) is generally safe in advanced cancer patients, used alone or with chemotherapy.
  • Anticancer chemotherapy is known to cause cardiotoxicity, leading to cardiomyopathy.
  • There is a need for therapeutic strategies to mitigate chemotherapy-induced heart damage.

Purpose of the Study:

  • To investigate the potential cardioprotective effects of TRAIL administration.
  • To determine if TRAIL can prevent or reduce the development of cardiomyopathy.
  • To evaluate TRAIL's efficacy in a relevant disease model.

Main Methods:

  • Administration of TRAIL, including recombinant soluble TRAIL and adeno-associated virus (AAV)-TRAIL expression vector.
  • Utilized the ApoE(-/-) diabetic mouse model, a model susceptible to cardiovascular complications.
  • Assessed the development of cardiomyopathy in treated and control groups.

Main Results:

  • TRAIL administration, in both forms tested, significantly reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model.
  • These findings were observed in a model that mimics conditions associated with cardiovascular risk.

Conclusions:

  • Therapeutic administration of TRAIL may possess a cardioprotective effect against chemotherapy-induced cardiotoxicity.
  • This study provides the first evidence suggesting TRAIL as a potential agent for preventing heart damage during cancer treatment.